Statins and risk of cancer: A systematic review and metaanalysis

被引:183
作者
Browning, Danielle R. L.
Martin, Richard M.
机构
[1] Univ Bristol, Dept Social Med, Bristol, Avon, England
[2] Univ Bristol, Fac Med & Dent, Bristol, Avon, England
关键词
statins; HMG-CoA reductase inhibitors; cancer; neoplasia;
D O I
10.1002/ijc.22366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We conducted a systematic review of the association between HMG-CoA reductase inhibitor (statin) use and cancer risk. We searched MEDLINE, EMBASE, Web of Science, ISI Proceedings and BIOSIS Previews bibliographic databases, electronic trials registers and reference lists for potentially eligible randomized trials and observational studies. Thirty-eight individual studies (26 randomized trials involving 103,573 participants and 12 observational studies with 826,854 participants) were included. Median follow-up was 3.6 and 6.2 years for trials and observational studies, respectively. In metaanalyses of randomized trials, there was no evidence that statin therapy was associated with incidence of all-cancers (26 trials; pooled risk ratio = 1.00; 95% Cl 0.95-1.05; I-2 = 0%) or the following site-specific cancers: breast (7 trials; risk ratio = 1.01; 0.79-1.30; I-2 = 43%), prostate (4 trials; risk ratio = 1.00; 0.85-1.17; 12 = 0%), colorectum (9 trials; risk ratio = 1.02; 0.89-1.16; I-2 = 0%), lung (9 trials; risk ratio = 0.96; 0.841.09. I-2 = 0%), genito-urinary (5 trials; risk ratio = 0.95; 0.83-log. I-2 = 0%); 3, melanoma (4 trials; risk ratio = 0.86; 0.62-1.20; I-2 = 17%) or gastric (1 trial; risk ratio = 1.00; 0.35-2.85). There was no evidence of differential effects by length of follow-up, statin type (lipophilic vs. lipophobic) or potency. Trial results were generally consistent with observational studies. We conclude that statin use is not associated with short-term cancer risk, but longer-latency effects remain possible. (c) 2006 Wiley-Liss. Inc.
引用
收藏
页码:833 / 843
页数:11
相关论文
共 72 条
[1]  
[Anonymous], 2000, ITAL HEART J
[2]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[3]   Statin use and the risk of breast cancer [J].
Beck, P ;
Wysowski, DK ;
Downey, W ;
Butler-Jones, D .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (03) :280-285
[4]   Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease [J].
Beishuizen, ED ;
Van de Ree, MA ;
Jukema, JW ;
Tamsma, JT ;
Van der Vijver, JCM ;
Meinders, AE ;
Putter, H ;
Huisman, MV .
DIABETES CARE, 2004, 27 (12) :2887-2892
[5]   Long-term persistence in use of statin therapy in elderly patients [J].
Benner, JS ;
Glynn, RJ ;
Mogun, H ;
Neumann, PJ ;
Weinstein, MC ;
Avorn, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04) :455-461
[6]   Do statins cause cancer? A meta-analysis of large randomized clinical trials [J].
Bjerre, LM ;
LeLorier, J .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (09) :716-723
[7]   CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS) [J].
BLANKENHORN, DH ;
AZEN, SP ;
KRAMSCH, DM ;
MACK, WJ ;
CASHINHEMPHILL, L ;
HODIS, HN ;
DEBOER, LWV ;
MAHRER, PR ;
MASTELLER, MJ ;
VAILAS, LI ;
ALAUPOVIC, P ;
HIRSCH, LJ .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :969-976
[8]   Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies [J].
Bonovas, S ;
Filioussi, K ;
Tsavaris, N ;
Sitaras, NM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8606-8612
[9]   The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women - A case-control study [J].
Boudreau, DM ;
Gardner, JS ;
Malone, KE ;
Heckbert, SR ;
Blough, DK ;
Daling, JR .
CANCER, 2004, 100 (11) :2308-2316
[10]   EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA [J].
BRADFORD, RH ;
SHEAR, CL ;
CHREMOS, AN ;
DUJOVNE, C ;
DOWNTON, M ;
FRANKLIN, FA ;
GOULD, AL ;
HESNEY, M ;
HIGGINS, J ;
HURLEY, DP ;
LANGENDORFER, A ;
NASH, DT ;
POOL, JL ;
SCHNAPER, H .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :43-49